IOVA

Iovance Biotherapeutics Inc

14.77

Oct 21 • 2:13 PM ET -0.09 (-0.57%)

Healthcare Biotechnology USA Mid NASD

Peers: OBX IMTX IMCR LYEL REPL LEGN IBRX AUTL BMY MRK

| Held by: VTI XBI IWM VB VXF IWN IBB VTWO SCHA DFAS

Index	RUT
Market Cap	6.69B
Enterprise Value	6.44B
Income	-289.52M
Sales	324.91M
Book/sh	1.62
Cash/sh	0.66
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	975
IPO	Sep 01, 2009

P/E	-
Forward P/E	-
PEG	-
P/S	20.60
P/B	9.09
P/C	22.48
P/FCF	-
EV/EBITDA	-
EV/Sales	19.82
Quick Ratio	3.82
Current Ratio	4.35
Debt/Eq	0.06
LT Debt/Eq	0.06
Option/Short	Yes / Yes

EPS (ttm)	-0.72
EPS next Y	-0.17
EPS next Q	-0.08
EPS this Y	59.29%
EPS next Y	61.46%
EPS next 5Y	-
EPS past 3/5Y	23.93% 10.23%
Sales past 3/5Y	- -
EPS Y/Y TTM	41.20%
Sales Y/Y TTM	34.52%
EPS Q/Q	68.51%
Sales Q/Q	65.65%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	17.60% 13.07%

Insider Own	12.96%
Insider Trans	0.00%
Inst Own	57.82%
Inst Trans	5.15%
ROA	-31.76%
ROE	-40.36%
ROIC	-37.15%
Gross Margin	37.14%
Oper. Margin	-91.17%
Profit Margin	-89.11%
SMA20	7.88%
SMA50	39.23%
SMA200	169.73%
Trades

Shs Outstand	452.97M
Shs Float	394.26M
Short Float	16.44%
Short Ratio	3.89
Short Interest	64.83M
52W High	15.30 -3.43%
52W Low	1.76 739.49%
Volatility	6.84% 7.20%
ATR (14)	0.89
RSI (14)	65.69
Beta	0.80
Rel Volume	0.63
Avg Volume	16.65M
Volume	7,777,383

Perf Week	3.98%
Perf Month	38.86%
Perf Quarter	188.01%
Perf Half Y	318.56%
Perf YTD	441.21%
Perf Year	550.88%
Perf 3Y	343.69%
Perf 5Y	-43.24%
Perf 10Y	129.07%
Recom	1.50
Target Price	14.40
Prev Close	14.86
Price	14.77
Change %	-0.57%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-26	Resumed	Goldman	Buy	$15
Feb-25-26	Upgrade	Citizens	Mkt Perform → Mkt Outperform	$5
Jul-15-25	Downgrade	Goldman	Neutral → Sell	$1
May-16-25	Downgrade	UBS	Buy → Neutral	$2
May-12-25	Downgrade	Truist	Buy → Hold
May-09-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Oct-24-24	Initiated	UBS	Buy	$17
Jul-29-24	Downgrade	Piper Sandler	Overweight → Neutral	$19 → $10
Nov-20-23	Initiated	Goldman	Buy	$12
Sep-18-23	Reiterated	Barclays	Overweight	$40 → $18
May-30-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$11 → $17
Mar-27-23	Resumed	Wells Fargo	Equal Weight	$11
Jan-27-23	Upgrade	Piper Sandler	Neutral → Overweight	$11 → $14
Dec-09-22	Downgrade	Goldman	Buy → Neutral	$20 → $6
Oct-31-22	Initiated	Guggenheim	Neutral
Aug-18-22	Resumed	Wells Fargo	Equal Weight	$14
Jan-28-22	Upgrade	Stifel	Hold → Buy	$23 → $25
Dec-07-21	Resumed	Cowen	Outperform
Jun-10-21	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$32
May-20-21	Downgrade	Piper Sandler	Overweight → Neutral	$35 → $18

Show Previous Ratings

Oct-19-26 07:00AM	Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026 (GlobeNewswire)
Oct-16-26 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -7.47%
Oct-01-26 07:00AM	Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Sep-29-26 11:47PM	Biotech Lagged The Broader Market In September Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBIs Slump? (Stocktwits) +31.48%
10:57PM	Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today? (Stocktwits)
12:06PM	Loading…
12:06PM	Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth (Barrons.com)
10:15AM	IOVA Stock Hits Over 2-Year Highs Why Iovance Raised Its FY2026 Revenue Outlook (Stocktwits)
09:33AM	Iovance Raises 2026 Revenue Guidance to $410 Million-$420 Million (InvestorsHub)
09:23AM	Iovance shares jump in premarket as raised outlook clears consensus views (Investing.com)
07:00AM	Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million (GlobeNewswire)
Sep-18-26 05:10PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-17-26 11:47PM	Why Did CRWD, OKTA, IOVA Shares Climb To 52-Week Highs Today? (Stocktwits)
07:58AM	IOVA Stock Has Gained More Than 21% In Four Sessions, And Barclays Sees Another 52% Upside Potential - Heres Why (Stocktwits)
03:21AM	This Tiny Biotech Is Beating MRNA, IOVA And SLS Here's How A Billionaire Fueled Its September Rally (Stocktwits)
Sep-15-26 07:01PM	IOVA Flags Year-End Data Slate After Record Amtagvi Quarter, Highlights Clear Line Of Sight To Profitability (Stocktwits) +5.45%
07:11AM	Loading…
07:11AM	CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot (Stocktwits)
12:00AM	SLS, IBRX, IOVA In Focus Amid Big Pharmas Early Cancer-Asset Hunt: J&J Flags M&A Sweet Spot, Pfizer Eyes Phase 1-2 Deals (Stocktwits)
Sep-04-26 08:00AM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire)
Aug-21-26 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -7.79%
Aug-20-26 11:57PM	Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today? (Stocktwits) +12.52%
06:12PM	IOVA Stock Hits Fresh 52-Week Peak On UBS Target Hike, Melanoma Sector Optimism (Stocktwits)
Aug-19-26 05:23PM	IOVA Stock Hits New 52-Week High As Shares Jump 14% What Drove The Rally? (Stocktwits) +13.66%
Aug-18-26 09:54PM	Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today? (Stocktwits)
Aug-07-26 12:36PM	Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling. (Barrons.com)
08:30AM	Iovance Biotherapeutics, Inc. Q2 2026 Earnings Call Summary (Moby)
Aug-06-26 10:40PM	Why Did IOVA, REPL, ROKU Stocks Surge To 52-Week Highs Today? (Stocktwits) +43.09%
07:15PM	Iovance Biotherapeutics Inc (IOVA) (Q2 2026) Earnings Call Highlights: Record Revenue and ... (GuruFocus.com)
12:12PM	IOVA Stock Heads For Best Day In Over 6 Years Buyout Buzz Builds After Blowout Q2 (Stocktwits)
10:54AM	Iovance Biotherapeutics Reports Record Q2 Revenue and Reviews 2026 Outlook on Strong Amtagvi Demand (InvestorsHub)
07:55AM	Iovance Biotherapeutics: Q2 Earnings Snapshot (Associated Press)
07:01AM	Loading…
07:01AM	Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates (GlobeNewswire)
Jul-30-26 08:00AM	Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026 (GlobeNewswire)
Jul-17-26 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +7.30%
Jun-19-26 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-26 04:05PM	Iovance's Amtagvi (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia (GlobeNewswire) -7.56% +15.57%
Jun-01-26 07:30AM	Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001 (GlobeNewswire)
May-22-26 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +11.08%
May-21-26 08:05AM	Iovance Biotherapeutics to Present at Upcoming Conference (GlobeNewswire)
May-07-26 10:30AM	BC-Most Active Stocks (Associated Press) -13.20%
07:12AM	Iovance Biotherapeutics: Q1 Earnings Snapshot (Associated Press)
07:05AM	Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates (GlobeNewswire)
Apr-27-26 08:01AM	Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026 (GlobeNewswire)
Apr-17-26 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-15-26 05:13AM	Obsidian, Galera to advance cell therapy following reverse merger (BioPharma Dive)
Mar-31-26 08:49PM	The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step (PR Newswire) +5.72%
Mar-24-26 10:00AM	Advanced Cell-based Therapy Booming the Success for Healthcare Sector (PR Newswire)
Mar-20-26 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-07-26 08:10PM	Iovance (IOVA) Soars 33%, Hits All-Time High (Insider Monkey)
01:28AM	Iovance (IOVA) Hits 52-Week High as Analyst Doubles Price Target (Insider Monkey)
Mar-06-26 01:06PM	What's Going On With Iovance Biotherapeutics Stock On Friday? (Benzinga) +12.01%
12:01PM	UBS Raises PT on Iovance Biotherapeutics (IOVA) (Insider Monkey)
Mar-05-26 09:00AM	Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types (PR Newswire) +7.51%
Feb-26-26 02:27PM	Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success (Insider Monkey)
09:40AM	Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? (Zacks)
08:00AM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire)
Feb-25-26 01:33PM	Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why (24/7 Wall St.)
11:01AM	IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress (Zacks)
Feb-24-26 04:32PM	Iovance Biotherapeutics, Inc. Q4 2025 Earnings Call Summary (Moby) +30.80%
04:01PM	Iovance Biotherapeutics Inc (IOVA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
02:14PM	Iovance Biotherapeutics Explodes Over 20% - Early Trial Data Sparks Investor Frenzy (Benzinga)
12:49PM	Iovance Biotherapeutics Q4 Earnings Call Highlights (MarketBeat)
09:40AM	Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
09:02AM	IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential? (Zacks)
07:26AM	Iovance Biotherapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates (GlobeNewswire)
07:00AM	Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas (GlobeNewswire)
Feb-23-26 09:58AM	Iovance (IOVA) Shares New Amtagvi Data, Analysts Stay Positive (Insider Monkey)
Feb-20-26 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-26 09:58AM	Is Iovance Biotherapeutics Inc. (IOVA) One of the Best Immunotherapy Stocks to Buy According to Hedge Funds? (Insider Monkey)
Feb-17-26 08:41PM	Iovance Biotherapeutics Inc. (IOVA) Builds Momentum With New Trial Data (Insider Monkey)
Feb-11-26 06:39PM	Neurocrine Biosciences Q4 Earnings Call Highlights (MarketBeat)
04:05PM	Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 (GlobeNewswire)
Feb-06-26 11:02AM	Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure (Insider Monkey) +7.20%
Feb-05-26 05:15PM	Best-in-Class Real-World Data Support Early Amtagvi Treatment in Advanced Melanoma (GlobeNewswire)
Jan-16-26 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +6.31%
Jan-15-26 02:33PM	Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory (Insider Monkey) -6.72%
Dec-31-25 11:13AM	Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review (Insider Monkey)
Dec-29-25 09:50AM	2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street (Motley Fool)
Dec-19-25 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +12.10%
Dec-07-25 09:45AM	2 Stocks That Could Soar by 52% and 282%, According to Wall Street (Motley Fool)
Nov-21-25 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +11.61%
Nov-11-25 06:45AM	Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? (Motley Fool) +11.81%
Nov-07-25 01:45PM	IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y (Zacks)
08:45AM	2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street (Motley Fool)
Nov-06-25 09:15AM	Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +27.62%
08:19AM	Iovance Biotherapeutics: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results (GlobeNewswire)
Nov-05-25 05:20PM	Dynavax Technologies (DVAX) Surpasses Q3 Earnings Estimates (Zacks)
Nov-04-25 06:00PM	Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates (Zacks) -6.67%
Nov-03-25 10:00AM	Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline (Zacks)
07:00AM	Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) (GlobeNewswire)
Oct-23-25 04:05PM	Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025 (GlobeNewswire)
Oct-17-25 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +6.42%
06:17AM	Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health (Motley Fool)
Oct-15-25 08:45AM	Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge (PR Newswire) +5.66%
Oct-13-25 05:53AM	Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire? (Motley Fool)
Sep-20-25 02:43AM	Iovance Biotherapeutics, Inc. (IOVA) Targeting $1B on Amtagvi Sales amid Cost Cuts (Insider Monkey)
Sep-19-25 05:00PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -6.82%
10:05AM	Can This Beaten-Down Stock Bounce Back? (Motley Fool)
Sep-17-25 08:30AM	Advancing Cancer Research Brings New Hope for Patients Worldwide (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
Vogt Frederick G	Interim CEO & General Counsel	Sep 08 '26	Option Exercise	15,626	602,085	Sep 10 05:01 PM
BILINSKY IGOR	Chief Operating Officer	Sep 08 '26	Option Exercise	7,813	146,050	Sep 10 05:00 PM
Puri Raj K.	Chief Regulatory Officer	Sep 08 '26	Option Exercise	9,766	260,842	Sep 10 05:00 PM
Vogt Frederick G	Interim CEO & General Counsel	Sep 01 '26	Option Exercise	41,669	604,161	Sep 03 05:02 PM
Puri Raj K.	Chief Regulatory Officer	Sep 01 '26	Option Exercise	5,470	253,584	Sep 03 05:02 PM
BILINSKY IGOR	Chief Operating Officer	Sep 01 '26	Option Exercise	8,789	142,709	Sep 03 05:00 PM
Kirby Daniel Gordon	Chief Commercial Officer	Aug 10 '26	Option Exercise	10,001	156,947	Aug 12 05:30 PM
Roche Corleen M.	Chief Financial Officer	Aug 06 '26	Option Exercise	49,995	49,995	Aug 10 05:30 PM
Vogt Frederick G	Interim CEO & General Counsel	Jun 05 '26	Option Exercise	15,625	569,130	Jun 09 05:03 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jun 05 '26	Option Exercise	7,813	144,087	Jun 09 05:01 PM
Puri Raj K.	Chief Regulatory Officer	Jun 05 '26	Option Exercise	9,766	251,957	Jun 09 05:00 PM
BILINSKY IGOR	Chief Operating Officer	Jun 05 '26	Option Exercise	7,813	137,896	Jun 09 05:00 PM
Vogt Frederick G	Interim CEO & General Counsel	Jun 01 '26	Option Exercise	41,668	571,206	Jun 03 05:02 PM
Puri Raj K.	Chief Regulatory Officer	Jun 01 '26	Option Exercise	5,469	244,699	Jun 03 05:01 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jun 01 '26	Option Exercise	8,790	140,747	Jun 03 05:00 PM
BILINSKY IGOR	Chief Operating Officer	Jun 01 '26	Option Exercise	8,790	134,556	Jun 03 05:00 PM
Kirby Daniel Gordon	Chief Commercial Officer	May 11 '26	Option Exercise	10,000	149,381	May 13 05:00 PM
Vogt Frederick G	Interim CEO & General Counsel	Mar 05 '26	Option Exercise	62,493	556,293	Mar 06 05:02 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Mar 05 '26	Option Exercise	31,246	148,477	Mar 06 05:01 PM
Puri Raj K.	Chief Regulatory Officer	Mar 05 '26	Option Exercise	39,059	257,590	Mar 06 05:00 PM
BILINSKY IGOR	Chief Operating Officer	Mar 05 '26	Option Exercise	31,246	142,394	Mar 06 05:00 PM
Vogt Frederick G	Interim CEO & General Counsel	Mar 02 '26	Option Exercise	52,087	516,609	Mar 04 05:01 PM
BILINSKY IGOR	Chief Operating Officer	Mar 02 '26	Option Exercise	12,307	118,051	Mar 04 05:01 PM
Puri Raj K.	Chief Regulatory Officer	Mar 02 '26	Option Exercise	5,470	221,329	Mar 04 05:00 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Mar 02 '26	Option Exercise	12,697	124,353	Mar 04 05:00 PM
Kirby Daniel Gordon	Chief Commercial Officer	Feb 24 '26	Option Exercise	120,000	173,546	Feb 26 05:00 PM
Kirby Daniel Gordon	Chief Commercial Officer	Feb 10 '26	Option Exercise	39,996	69,996	Feb 12 05:00 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Dec 02 '25	Option Exercise	3,906	113,640	Dec 03 05:04 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Dec 01 '25	Option Exercise	8,789	114,198	Dec 03 05:04 PM
BILINSKY IGOR	Chief Operating Officer	Dec 02 '25	Option Exercise	3,516	107,530	Dec 03 05:02 PM
BILINSKY IGOR	Chief Operating Officer	Dec 01 '25	Option Exercise	8,789	108,478	Dec 03 05:02 PM
Vogt Frederick G	Interim CEO & General Counsel	Dec 02 '25	Option Exercise	10,417	468,948	Dec 03 05:01 PM
Vogt Frederick G	Interim CEO & General Counsel	Dec 01 '25	Option Exercise	41,669	476,232	Dec 03 05:01 PM
Puri Raj K.	Chief Regulatory Officer	Dec 01 '25	Option Exercise	5,469	218,326	Dec 03 05:00 PM

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

J.D.Dr. Frederick G. Vogt Esq.

Chief Financial OfficerMs. Corleen M. Roche

Chief Operating OfficerDr. Igor P. Bilinsky Ph.D.

Ph.D.Dr. Raj K. Puri M.D.

Chief Commercial OfficerMr. Daniel G. Kirby

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IOVA

Iovance Biotherapeutics Inc

Upgrade your Finviz experience